Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Halperin

Showing results (321-330 of 346) with videos related to

Pageof 35
Sort By:
Molecular Pharmaceutics|September 29, 2022
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided SurgeryServando Hernandez Vargas, Solmaz AghaAmiri, Sukhen C Ghosh, et al.
Pancreas|September 14, 2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant ChemotherapyReza Nejati, Jennifer B Goldstein, Daniel M Halperin, et al.
Pancreas|September 29, 2020
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine TumorsJennifer R Eads, Diane Reidy-Lagunes, Heloisa P Soares, et al.
Human Vaccines & Immunotherapeutics|January 8, 2025
Considering the impact of vaccine communication in the COVID-19 pandemic among adults in Canada: A qualitative study of lessons learned for future vaccine campaignsJeanna Parsons Leigh, Stephana Julia Moss, Jade MacDonald, et al.
Nature Medicine|October 8, 2021
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trialV Ratziu, L de Guevara, R Safadi, et al.
British Journal of Cancer|March 11, 2020
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trialsNamrata Vijayvergia, Arvind Dasari, Mengying Deng, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine TumorJin Guo, Kever A Lewis, Laura Prakash, et al.
Endocrine-Related Cancer|February 19, 2020
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directivesC R C Pieterman, S M Sadowski, J E Maxwell, et al.
Endocrine-Related Cancer|January 22, 2021
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasmsJames C Yao, Jonathan Strosberg, Nicola Fazio, et al.
Oral Oncology|March 9, 2024
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective studyL Guimaraes de Sousa, S Liu, P Bhosale, et al.
Pageof 35

Showing results (321-330 of 346) with videos related to

Sort By:
Pageof 35
Molecular Pharmaceutics|September 29, 2022
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided SurgeryServando Hernandez Vargas, Solmaz AghaAmiri, Sukhen C Ghosh, et al.
Pancreas|September 14, 2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant ChemotherapyReza Nejati, Jennifer B Goldstein, Daniel M Halperin, et al.
Pancreas|September 29, 2020
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine TumorsJennifer R Eads, Diane Reidy-Lagunes, Heloisa P Soares, et al.
Human Vaccines & Immunotherapeutics|January 8, 2025
Considering the impact of vaccine communication in the COVID-19 pandemic among adults in Canada: A qualitative study of lessons learned for future vaccine campaignsJeanna Parsons Leigh, Stephana Julia Moss, Jade MacDonald, et al.
Nature Medicine|October 8, 2021
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trialV Ratziu, L de Guevara, R Safadi, et al.
British Journal of Cancer|March 11, 2020
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trialsNamrata Vijayvergia, Arvind Dasari, Mengying Deng, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine TumorJin Guo, Kever A Lewis, Laura Prakash, et al.
Endocrine-Related Cancer|February 19, 2020
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directivesC R C Pieterman, S M Sadowski, J E Maxwell, et al.
Endocrine-Related Cancer|January 22, 2021
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasmsJames C Yao, Jonathan Strosberg, Nicola Fazio, et al.
Oral Oncology|March 9, 2024
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective studyL Guimaraes de Sousa, S Liu, P Bhosale, et al.
Pageof 35